Goldline Pharmaceutical IPO GMP & Allotment
Goldline Pharmaceutical is a SME IPO with a price band of Rs 41.00 to Rs 43.00 that listed on 19 May 2026 at a listing gain of +38.95%. Track its full GMP history, subscription data and listing details here.
- IPO Price Band
- ₹41.00 - ₹43.00
- Lot Size
- 3,000 Shares
- Bidding Closes
- 14 May 2026
- Listing Date
- 19 May 2026
Goldline Pharmaceutical IPO GMP Today & Key Takeaways
Goldline Pharmaceutical IPO officially listed on 19 May 2026 at Rs 59.75, delivering a +38.95% listing gain compared to its issue price of Rs 43.00. Pre-listing, its final recorded Grey Market Premium (GMP) was ₹16.75.
| Key Metric | Figure | Status / Context |
|---|---|---|
| Current GMP | ₹16.75 | +38.95% vs upper band (14 May 2026) |
| Est. Listing Price | ₹59.75 | +38.95% Est. Listing Gain |
| Price Band | ₹41.00 - ₹43.00 | SME IPO |
| Retail Minimum Investment | ₹2,58,000 | 2 Lot (3,000 Shares) |
| Bidding Window | 12 May 2026 – 14 May 2026 | Listed |
| Allotment & Listing Dates | Allotment: TBA | Listing: 19 May 2026 |
Complete IPO information
| IPO Open Date | 12 May 2026 |
|---|---|
| IPO Close Date | 14 May 2026 |
| IPO Price Band | ₹41.00 - ₹43.00 |
| Lot Size | 3,000 Shares |
| Current GMP | ₹16.75 |
| Estimated Listing Gain | +38.95% |
| Issue Size | - |
| Fresh Issue | - |
| Issue Type | SME |
| IPO Listing | NSE, BSE |
| Retail Quota | TBA |
| Registrar | TBA |
| Overall Subscription | 100.14x |
| Minimum Investment | ₹2,58,000 |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus | - |
IPO Snapshot & Investor Takeaways
At the upper end of its price band, Goldline Pharmaceutical is priced at ₹43 per share. With a minimum lot size of 3,000 shares, a retail investor applying for one lot would need approximately ₹2,58,000 to participate in this SME issue.
The latest recorded Grey Market Premium for Goldline Pharmaceutical stands at ₹16.75, implying an estimated listing gain of around 38.95% over the issue price if it holds until listing. GMP reflects informal grey-market sentiment rather than a guaranteed outcome, and can change at any point until the day of listing.
As of the latest update, Goldline Pharmaceutical's IPO was subscribed 100.14x overall, with a category-wise breakdown of Retail 139.51x, QIB 1.31x.
SME IPOs list on the dedicated SME platform of BSE/NSE. They usually involve smaller issue sizes and a higher per-lot investment than Mainboard issues, with comparatively lower institutional participation.
IPO roadmap at a glance
| Event / Milestone | Scheduled Date | Status |
|---|---|---|
| Bidding Opens | 12 May 2026 | Completed |
| Bidding Closes | 14 May 2026 | Completed |
| Allotment | TBA | Completed |
| Listing | 19 May 2026 | Completed |
Daily GMP status
| Date | GMP | Change | Gain |
|---|---|---|---|
| 14 May 2026 | ₹18.00 | - | 41.86% |
| 13 May 2026 | ₹18.00 | +₹1.00 | 41.86% |
| 12 May 2026 | ₹17.00 | - | 39.53% |
Application size breakdown
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 Lot | 6,000 | ₹2,58,000 |
| Retail Maximum | 2 Lot | 6,000 | ₹2,58,000 |
| S-HNI Minimum | 3 Lot | 9,000 | ₹3,87,000 |
| S-HNI Maximum | 7 Lot | 21,000 | ₹9,03,000 |
| B-HNI Minimum | 8 Lot | 24,000 | ₹10,32,000 |
Objects of the Issue & Official Documents
Goldline Pharmaceutical IPO Reservation
| Investor Category | Shares Offered | Shares (%) |
|---|---|---|
| Anchor Investor | 7,32,000 | 27.11% |
| QIB (Ex. Anchor) | 5,40,000 | 20.00% |
| NII | 3,90,000 | 14.44% |
| Retail | 9,00,000 | 33.33% |
Goldline Pharmaceutical IPO Anchor Investors
| Anchor Bidding Date | May 11, 2026 |
|---|---|
| Shares Offered | 7,32,000 |
| Anchor Size | — |
| Lock-in Period (50% Shares - 30 Days) | 2026 |
| Lock-in Period (50% Shares - 90 Days) | 2026 |
Goldline Pharmaceutical IPO Dates
| Particular | Dates |
|---|---|
| IPO Open Date | 12 May 2026 |
| IPO Close Date | 14 May 2026 |
| Basis of Allotment | - |
| Refunds | - |
| Credit to Demat Account | - |
| IPO Listing Date | 19 May 2026 |
Note: The timeline for Goldline Pharmaceutical IPO is tentative and subject to change.
Goldline Pharmaceutical IPO Promoters & Holding Pattern
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
| Promoter Holding Post Issue | 96,00,000 | — |
| Promoters |
|---|
| Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal |
Goldline Pharmaceutical Objects of the Issue & Utilisation of Proceeds
To Be Updated Soon
About Goldline Pharmaceutical IPO
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Goldline Ayushman, which includes Pediatricians, Child Specialists, Neonatologists, and General Practitioners, 4. Goldline InLife, which includes Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians, and 5. Goldline Wellness, which includes cancer therapy.
The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline.
Goldline Pharmaceutical Company Financials
To Be Updated Soon
Goldline Pharmaceutical Company Valuation – FY2026
To Be Updated Soon
Goldline Pharmaceutical IPO Peer Group Comparison
To Be Updated Soon
IPO Lead Managers aka Merchant Bankers
IPO Lead Managers aka Merchant Bankers
- Cumulative Capital Pvt. Ltd.
Compare Goldline Pharmaceutical IPO with similar IPOs
Goldline Pharmaceutical IPO FAQs
Comments
Share a useful question or insight about Goldline Pharmaceutical.
Leave a comment
Your email address will not be published. All comments and replies are reviewed before appearing.
Loading comments...